Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

2,534 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study.
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, Ciruelos E, Schneeweiss A, Loi S, Monturus E, Clark E, Knott A, Restuccia E, Benyunes MC, Cortés J; CLEOPATRA study group. Swain SM, et al. Among authors: kim sb. Lancet Oncol. 2020 Apr;21(4):519-530. doi: 10.1016/S1470-2045(19)30863-0. Epub 2020 Mar 12. Lancet Oncol. 2020. PMID: 32171426 Clinical Trial.
Docetaxel plus epirubicin as first-line chemotherapy in MBC (KCSG 01-10-05): phase II trial and the predictive values of circulating HER2 extracellular domain and vascular endothelial growth factor.
Im SA, Kim SB, Lee MH, Im YH, Lee KH, Song HS, Lee MA, Lee J, Lee NS, Ham HS, Kim TY, Park YH, Lee KE, Kim KW, Seo JH, Lee SN, Hong YS, Bang YJ, Kim WK, Park HS. Im SA, et al. Among authors: kim sb, kim wk, kim ty, kim kw. Oncol Rep. 2005 Aug;14(2):481-7. Oncol Rep. 2005. PMID: 16012734 Clinical Trial.
Capecitabine and cisplatin chemotherapy (XP) alone or sequentially combined chemoradiotherapy containing XP regimen in patients with three different settings of stage IV esophageal cancer.
Lee SS, Kim SB, Park SI, Kim YH, Ryu JS, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Cho KJ, Kim JH. Lee SS, et al. Among authors: kim sb, kim yh, kim jh. Jpn J Clin Oncol. 2007 Nov;37(11):829-35. doi: 10.1093/jjco/hym117. Epub 2007 Oct 19. Jpn J Clin Oncol. 2007. PMID: 17951334
Initial stage affects survival even after complete pathologic remission is achieved in locally advanced esophageal cancer: analysis of 70 patients with pathologic major response after preoperative chemoradiotherapy.
Kim MK, Cho KJ, Park SI, Kim YH, Kim JH, Song HY, Shin JH, Jung HY, Lee GH, Choi KD, Song HJ, Ryu JS, Kim SB. Kim MK, et al. Among authors: kim yh, kim sb, kim jh. Int J Radiat Oncol Biol Phys. 2009 Sep 1;75(1):115-21. doi: 10.1016/j.ijrobp.2008.10.074. Epub 2009 Feb 27. Int J Radiat Oncol Biol Phys. 2009. PMID: 19251379
Usefulness of interim FDG-PET after induction chemotherapy in patients with locally advanced squamous cell carcinoma of the head and neck receiving sequential induction chemotherapy followed by concurrent chemoradiotherapy.
Yoon DH, Cho Y, Kim SY, Nam SY, Choi SH, Roh JL, Lee SW, Song SY, Lee JH, Kim JS, Cho KJ, Kim SB. Yoon DH, et al. Among authors: kim sb, kim sy, kim js. Int J Radiat Oncol Biol Phys. 2011 Sep 1;81(1):118-25. doi: 10.1016/j.ijrobp.2010.04.034. Epub 2010 Aug 2. Int J Radiat Oncol Biol Phys. 2011. PMID: 20675065
Zoledronic acid prevents bone loss in premenopausal women with early breast cancer undergoing adjuvant chemotherapy: a phase III trial of the Korean Cancer Study Group (KCSG-BR06-01).
Kim JE, Ahn JH, Jung KH, Kim SB, Kim HJ, Lee KS, Ro JS, Park YH, Ahn JS, Im YH, Im SA, Lee MH, Kim SY. Kim JE, et al. Among authors: kim sb, kim hj, kim sy. Breast Cancer Res Treat. 2011 Jan;125(1):99-106. doi: 10.1007/s10549-010-1201-8. Epub 2010 Oct 5. Breast Cancer Res Treat. 2011. PMID: 20922564 Clinical Trial.
2,534 results